{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:52:12Z","timestamp":1791413532189,"version":"4.3.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,11,20]],"date-time":"2013-11-20T00:00:00Z","timestamp":1384905600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s00109-013-1102-5","type":"journal-article","created":{"date-parts":[[2013,11,19]],"date-time":"2013-11-19T04:33:20Z","timestamp":1384835600000},"page":"151-164","source":"Crossref","is-referenced-by-count":103,"title":["Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer"],"prefix":"10.1007","volume":"92","author":[{"given":"Lisha","family":"Xiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele M.","family":"Gilkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallavi","family":"Chaturvedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibo","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoharu","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houjie","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg L.","family":"Semenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,20]]},"reference":[{"key":"1102_CR1","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1089\/ars.2007.1628","volume":"9","author":"P Vaupel","year":"2007","unstructured":"Vaupel P, Hockel M, Mayer A (2007) Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox Signal 9:1221\u20131235","journal-title":"Antioxid Redox Signal"},{"key":"1102_CR2","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.1038\/onc.2012.578","volume":"32","author":"GL Semenza","year":"2013","unstructured":"Semenza GL (2013) Cancer-stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis. Oncogene 32:4057\u20134063","journal-title":"Oncogene"},{"key":"1102_CR3","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1172\/JCI67230","volume":"123","author":"GL Semenza","year":"2013","unstructured":"Semenza GL (2013) HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest 123:3664\u20133671","journal-title":"J Clin Invest"},{"key":"1102_CR4","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1128\/MCB.16.9.4604","volume":"16","author":"JA Forsythe","year":"1996","unstructured":"Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16:4604\u20134613","journal-title":"Mol Cell Biol"},{"key":"1102_CR5","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1038\/nm1075","volume":"10","author":"DJ Ceradini","year":"2004","unstructured":"Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, Capla JM, Galiano RD, Levine JP, Gurtner GC (2004) Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10:858\u2013864","journal-title":"Nat Med"},{"key":"1102_CR6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1172\/JCI69244","volume":"123","author":"P Chaturvedi","year":"2013","unstructured":"Chaturvedi P, Gilkes DM, Wong CC, Kshitiz LW, Zhang H, Wei H, Takano N, Schito L, Levchenko A et al (2013) Hypoxia-inducible factor-dependent breast cancer-mesenchymal stem cell bidirectional signaling promotes metastasis. J Clin Invest 123:189\u2013205","journal-title":"J Clin Invest"},{"key":"1102_CR7","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4048\/jbc.2011.14.2.88","volume":"14","author":"JY Choi","year":"2011","unstructured":"Choi JY, Jang YS, Min SY, Song JY (2011) Overexpression of MMP-9 and HIF-1\u03b1 in breast cancer cells under hypoxic conditions. J Breast Cancer 14:88\u201395","journal-title":"J Breast Cancer"},{"key":"1102_CR8","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1158\/0008-5472.CAN-12-3963","volume":"73","author":"DM Gilkes","year":"2013","unstructured":"Gilkes DM, Chaturvedi P, Bajpai S, Wong CC, Wei H, Pitcairn S, Hubbi ME, Wirtz D, Semenza GL (2013) Collagen prolyl hydroxylases are essential for breast cancer metastasis. Cancer Res 73:3285\u20133296","journal-title":"Cancer Res"},{"key":"1102_CR9","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/nature04695","volume":"440","author":"JT Erler","year":"2006","unstructured":"Erler JT, Bennewith KL, Nicolau M, Dornh\u00f6fer N, Kong C, Le QT, Chi JT, Jeffrey SS, Giaccia AJ (2006) Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440:1222\u20131226","journal-title":"Nature"},{"key":"1102_CR10","doi-asserted-by":"crossref","first-page":"16369","DOI":"10.1073\/pnas.1113483108","volume":"108","author":"CC Wong","year":"2011","unstructured":"Wong CC, Gilkes DM, Zhang H, Chen J, Wei H, Chaturvedi P, Fraley SI, Wong CM, Khoo US, Ng IO et al (2011) Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proc Natl Acad Sci U S A 108:16369\u201316374","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1102_CR11","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1038\/onc.2011.365","volume":"31","author":"H Zhang","year":"2012","unstructured":"Zhang H, Wong CC, Wei H, Gilkes DM, Korangath P, Chaturvedi P, Schito L, Chen J, Krishnamachary B, Winnard PT Jr et al (2012) HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene 31:1757\u20131770","journal-title":"Oncogene"},{"key":"1102_CR12","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1073\/pnas.1018866109","volume":"109","author":"SJ Conley","year":"2012","unstructured":"Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN, Clouthier SG, Wicha MS (2012) Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A 109:2784\u20132789","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1102_CR13","doi-asserted-by":"crossref","first-page":"R6","DOI":"10.1186\/bcr3087","volume":"14","author":"LP Schwab","year":"2012","unstructured":"Schwab LP, Peacock DL, Majumdar D, Ingels JF, Jensen LC, Smith KD, Cushing RC, Seagroves TN (2012) Hypoxia-inducible factor 1\u03b1 promotes primary tumor growth and tumor-initiating cell activity in breast cancer. Breast Cancer Res 14:R6","journal-title":"Breast Cancer Res"},{"key":"1102_CR14","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1073\/pnas.92.12.5510","volume":"92","author":"GL Wang","year":"1995","unstructured":"Wang GL, Jiang BH, Rue EA, Semenza GL (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 92:5510\u20135514","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1102_CR15","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1152\/physrev.00030.2011","volume":"92","author":"NR Prabhakar","year":"2012","unstructured":"Prabhakar NR, Semenza GL (2012) Adaptive and maladaptive cardiorespiratory responses to continuous and intermittent hypoxia mediated by hypoxia-inducible factors 1 and 2. Physiol Rev 92:967\u20131003","journal-title":"Physiol Rev"},{"key":"1102_CR16","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0014-5793(99)01359-9","volume":"460","author":"E Minet","year":"1999","unstructured":"Minet E, Mottet D, Michel G, Roland I, Raes M, Remacle J, Michiels C (1999) Hypoxia-induced activation of HIF-1: role of HIF-1\u03b1-Hsp90 interaction. FEBS Lett 460:251\u2013256","journal-title":"FEBS Lett"},{"key":"1102_CR17","doi-asserted-by":"crossref","first-page":"29936","DOI":"10.1074\/jbc.M204733200","volume":"277","author":"JS Isaacs","year":"2002","unstructured":"Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM (2002) Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1\u03b1-degradative pathway. J Biol Chem 277:29936\u201329944","journal-title":"J Biol Chem"},{"key":"1102_CR18","doi-asserted-by":"crossref","first-page":"16128","DOI":"10.1074\/jbc.M313342200","volume":"279","author":"JS Isaacs","year":"2004","unstructured":"Isaacs JS, Jung YJ, Neckers L (2004) Aryl hydrocarbon nuclear translocator (ARNT) promotes oxygen-independent stabilization of hypoxia-inducible factor-1\u03b1 by modulating an Hsp90-dependent regulatory pathway. J Biol Chem 279:16128\u201316135","journal-title":"J Biol Chem"},{"key":"1102_CR19","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000080345","volume":"14","author":"DM Katschinski","year":"2004","unstructured":"Katschinski DM, Schindler SG, Thomas T, Voss AK, Wenger RH (2004) Interaction of the PAS B domain with HSP90 accelerates hypoxia-inducible factor 1\u03b1 stabilization. Cell Physiol Biochem 14:351\u2013360","journal-title":"Cell Physiol Biochem"},{"key":"1102_CR20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.molcel.2007.01.001","volume":"25","author":"YV Liu","year":"2007","unstructured":"Liu YV, Baek JH, Zhang H, Diez R, Cole RN, Semenza GL (2007) RACK1 competes with HSP90 for binding to HIF-1\u03b1 and is required for O2-independent and HSP90 inhibitor-induced degradation of HIF-1\u03b1. Mol Cell 25:207\u2013217","journal-title":"Mol Cell"},{"key":"1102_CR21","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1470-2045(07)70074-8","volume":"8","author":"S Cleator","year":"2007","unstructured":"Cleator S, Heller W, Coombes RC (2007) Triple-negative breast cancer: therapeutic options. Lancet Oncol 8:235\u2013244","journal-title":"Lancet Oncol"},{"key":"1102_CR22","doi-asserted-by":"crossref","first-page":"8368","DOI":"10.1073\/pnas.0903392106","volume":"106","author":"E Caldas-Lopes","year":"2009","unstructured":"Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, Rodina A, Moulick K, Taldone T, Gozman A, Guo Y et al (2009) Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A 106:8368\u20138373","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1102_CR23","doi-asserted-by":"crossref","first-page":"5432","DOI":"10.1158\/1078-0432.CCR-11-0592","volume":"17","author":"PP Mehta","year":"2011","unstructured":"Mehta PP, Whalen P, Baxi SM, Kung PP, Yamazaki S, Yin M (2011) Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp90. Clin Cancer Res 17:5432\u20135442","journal-title":"Clin Cancer Res"},{"key":"1102_CR24","doi-asserted-by":"crossref","unstructured":"Friedland JC, Smith DL, Sang J, Acquaviva J, He S, Zhang C, Proia DA (2013) Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes. Invest New Drugs 2013 May 18 [Epub ahead of print]","DOI":"10.1007\/s10637-013-9971-6"},{"key":"1102_CR25","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1158\/1535-7163.MCT-11-0755","volume":"11","author":"W Ying","year":"2012","unstructured":"Ying W, Du Z, Sun L, Foley KP, Proia DA, Blackman RK, Zhou D, Inoue T, Tatsuta N, Sang J et al (2012) Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther 11:475\u2013484","journal-title":"Mol Cancer Ther"},{"key":"1102_CR26","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1158\/1078-0432.CCR-11-2967","volume":"18","author":"T Shimamura","year":"2012","unstructured":"Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ, Inoue T, Chen L, Li D, Carretero J, Li Y et al (2012) Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clin Cancer Res 18:4973\u20134985","journal-title":"Clin Cancer Res"},{"key":"1102_CR27","doi-asserted-by":"crossref","first-page":"E2707","DOI":"10.1073\/pnas.1214019109","volume":"109","author":"L Schito","year":"2012","unstructured":"Schito L, Rey S, Tafani M, Zhang H, Wong CC, Russo A, Russo MA, Semenza GL (2012) Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells. Proc Natl Acad Sci U S A 109:E2707\u2013E2716","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1102_CR28","doi-asserted-by":"crossref","first-page":"17910","DOI":"10.1073\/pnas.0909353106","volume":"106","author":"K Lee","year":"2009","unstructured":"Lee K, Zhang H, Qian DZ, Rey S, Liu JO, Semenza GL (2009) Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc Natl Acad Sci U S A 106:17910\u201317915","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1102_CR29","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0076-6879(07)35017-9","volume":"435","author":"B Krishnamachary","year":"2007","unstructured":"Krishnamachary B, Semenza GL (2007) Analysis of hypoxia-inducible factor 1\u03b1 expression and its effects on invasion and metastasis. Methods Enzymol 435:347\u2013354","journal-title":"Methods Enzymol"},{"key":"1102_CR30","first-page":"291","volume":"23","author":"AC Ruifrok","year":"2001","unstructured":"Ruifrok AC, Johnston DA (2001) Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol 23:291\u2013299","journal-title":"Anal Quant Cytol Histol"},{"key":"1102_CR31","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/jnci\/53.3.661","volume":"53","author":"R Cailleau","year":"1974","unstructured":"Cailleau R, Young R, Olive M, Reeves WJ Jr (1974) Breast tumor cell lines from pleural effusions. J Natl Cancer Inst 53:661\u2013674","journal-title":"J Natl Cancer Inst"},{"key":"1102_CR32","doi-asserted-by":"crossref","first-page":"5292","DOI":"10.1158\/0008-5472.CAN-09-1528","volume":"69","author":"AF Chambers","year":"2009","unstructured":"Chambers AF (2009) MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? Cancer Res 69:5292\u20135293","journal-title":"Cancer Res"},{"key":"1102_CR33","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/0008-5472.CAN-08-2741","volume":"69","author":"E Charafe-Jauffret","year":"2009","unstructured":"Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J et al (2009) Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 69:1302\u20131313","journal-title":"Cancer Res"},{"key":"1102_CR34","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.stem.2007.08.014","volume":"1","author":"C Ginestier","year":"2007","unstructured":"Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S et al (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1:555\u2013567","journal-title":"Cell Stem Cell"},{"key":"1102_CR35","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.4161\/cc.10.9.15486","volume":"10","author":"P Marcato","year":"2011","unstructured":"Marcato P, Dean CA, Giacomantonio CA, Lee PW (2011) Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform. Cell Cycle 10:1378\u20131384","journal-title":"Cell Cycle"},{"key":"1102_CR36","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s10456-013-9364-7","volume":"16","author":"PN Ganji","year":"2013","unstructured":"Ganji PN, Park W, Wen J, Mahaseth H, Landry J, Farris AB, Willingham F, Sullivan PS, Proia DA, El-Hariry I et al (2013) Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1\u03b1 and STAT-3. Angiogenesis 16:903\u2013917","journal-title":"Angiogenesis"},{"key":"1102_CR37","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1172\/JCI65416","volume":"123","author":"NE Bhola","year":"2013","unstructured":"Bhola NE, Balko JM, Dugger TC, Kuba MG, Sanchez V, Sanders M, Stanford J, Cook RS, Arteaga CL (2013) TGF-\u03b2 inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest 123:1348\u20131358","journal-title":"J Clin Invest"},{"key":"1102_CR38","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"The Cancer Genome Atlas Network","year":"2012","unstructured":"The Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumors. Nature 490:61\u201370","journal-title":"Nature"},{"key":"1102_CR39","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/onc.2009.441","volume":"29","author":"GL Semenza","year":"2010","unstructured":"Semenza GL (2010) Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29:625\u2013634","journal-title":"Oncogene"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-013-1102-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00109-013-1102-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-013-1102-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T12:39:41Z","timestamp":1564749581000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00109-013-1102-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,20]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["1102"],"URL":"https:\/\/doi.org\/10.1007\/s00109-013-1102-5","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,20]]}}}